Elevance Health (ELV) Cash & Equivalents (2009 - 2026)

Elevance Health (ELV) has reported Cash & Equivalents for 18 consecutive years, with $10.2 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash & Equivalents rose 19.53% year-over-year to $10.2 billion; the TTM figure through Jun 2026 stood at $10.2 billion (up 19.53% YoY), while the FY2025 annual figure was $9.5 billion, up 14.51% from the prior year.
• Cash & Equivalents advanced to $10.2 billion in Q2 2026 per ELV's latest filing, from $9.7 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $10.9 billion in Q3 2023 and bottomed at $6.2 billion in Q1 2022.
• Historically, Cash & Equivalents has averaged $8.3 billion across 5 years, with a median of $8.4 billion in 2024.
• Annual changes were most pronounced in 2023 — Cash & Equivalents soared 64.62% — and 2024, when it plunged 38.61%.
• Elevance Health's Cash & Equivalents stood at $7.4 billion in 2022, then dropped by 11.66% to $6.5 billion in 2023, then rose by 27.0% to $8.3 billion in 2024, then grew by 14.51% to $9.5 billion in 2025, then grew by 7.81% to $10.2 billion in 2026.
• Business Quant data shows ELV's Cash & Equivalents at $10.2 billion in Q2 2026, $9.7 billion in Q1 2026, and $9.5 billion in Q4 2025.